5 Things You Should Know About Human Metapneumovirus and How It Spreads

Human metapneumovirus (HMPV) is a respiratory virus that can cause symptoms similar to the common cold, flu, or even pneumonia. Discovered in 2001, HMPV is part of the paramyxovirus family, which also includes viruses like the respiratory syncytial virus (RSV). While human metapneumovirus primarily affects children, the elderly, and individuals with weakened immune systems, it can also cause respiratory illness in healthy adults.

Human metapneumovirus is transmitted through respiratory droplets, making it highly contagious, especially in crowded environments like schools and daycare centers. In this article, “5 Things You Should Know About Human Metapneumovirus and How It Spreads,” we’ll explore the key facts about this virus, including its symptoms, transmission, and who is most at risk. By understanding how HMPV spreads and how to protect yourself, you can take proactive steps to reduce your risk of infection and prevent its spread to others.

What is Human Metapneumovirus?

Human metapneumovirus (HMPV) is a ubiquitous respiratory pathogen that, despite being a major driver of global illness, remained hidden from medical science until its discovery in 2001. As a member of the Pneumoviridae family, the hmpv virus is a single-stranded RNA virus that serves as a sibling to the well-known Respiratory Syncytial Virus (RSV). This virus is so prevalent that nearly every child on Earth has been infected by the age of five. It primarily targets the delicate lining of the respiratory tract, from the nasal passages down to the deep air sacs of the lungs, making it a frequent cause of both upper and lower respiratory infections.

The biological “machinery” of human metapneumovirus hmpv is defined by its viral envelope, which is studded with specialized fusion (F) and attachment (G) glycoproteins. These proteins act as molecular keys, allowing the virus to latch onto and invade host cells. Once the hmpv infection takes hold, the virus hijacks the cellular environment to replicate, triggering an inflammatory immune response that results in the classic symptoms of respiratory distress.

Interestingly, the body’s immune memory for h metapneumovirus is notoriously short-lived; unlike the “one-and-done” nature of some childhood diseases, reinfection with human metapneumovirus is a common occurrence throughout a person’s life, though the severity typically wanes after the initial exposure in infancy.

Recognizing the Spectrum: HMPV Symptoms

The hmpv symptoms can be deceptively simple, often masquerading as a standard winter cold. Because the virus targets the same pathways as influenza and RSV, the clinical manifestations of metapneumovirus usually involve a combination of congestion, fever, and a persistent, rasping cough. For most healthy individuals, the infection is a self-limiting annoyance that resolves within 10 to 14 days without the need for intensive medical intervention. However, the profile of hmpv symptoms adults and children experience can diverge sharply based on the “depth” of the infection.

• Upper Respiratory Symptoms: Most common in healthy adults, these include rhinorrhea (runny nose), sore throat, and mild fatigue.
• Lower Respiratory Symptoms: When the virus migrates into the lungs, it causes more severe hmpv symptoms such as wheezing, tachypnea (rapid breathing), and shortness of breath. In children, this often manifests as bronchiolitis—an inflammation of the smallest airways—while in vulnerable populations, it can progress rapidly to human metapneumovirus pneumonia.

The Clinical Shadow: HMPV in Adults and High-Risk Groups

While often discussed in pediatric circles, human metapneumovirus in adults represents a significant burden on the healthcare system, particularly during the late winter and spring months. In the elderly or those with underlying pulmonary issues like COPD or asthma, the virus acts as an “exacerbator,” pushing the respiratory system past its limit. A standard hmpv infection in a 70-year-old can be just as dangerous as a case of influenza, leading to severe viral hmpv pneumonia that requires supplemental oxygen and hospitalization.

The danger of human metapneumovirus pneumonia lies in the inflammation it triggers deep within the alveoli. This inflammation prevents efficient oxygen exchange, leading to a “crackling” sound in the lungs and visible distress. Because the symptoms of hmpv pneumonia are clinically indistinguishable from other viral or bacterial lung infections, doctors must rely on specific diagnostic tools to identify the culprit. This is where the metapneumovirus rna comes into play; by using a human metapneumovirus pcr test, clinicians can detect the genetic signature of the virus in a nasal swab, ensuring that the patient isn’t unnecessarily treated with antibiotics for a viral pathogen.

Viral Siblings: HMPV vs. RSV

The relationship between human metapneumovirus hmpv and RSV is so close that they are often referred to as “clinical twins.” Before 2001, thousands of respiratory cases were labeled as “RSV-negative bronchiolitis” because physicians lacked the tools to identify the hmpv virus. Both viruses share a similar seasonal peak and target the same high-risk groups, including infants and the immunocompromised.

The biological similarity extends to their entry mechanisms; both utilize fusion proteins to merge with human cells, which is why their human metapneumovirus symptoms are nearly identical. This shared biology is a primary reason why researchers are looking for cross-reactive treatments. However, because the metapneumovirus infection can occur simultaneously with RSV or the flu, the severity of the respiratory distress can be compounded, making the use of a metapneumovirus pcr even more vital for accurate patient triage.

The Modes of Human Metapneumovirus Transmission

The successful circulation of human metapneumovirus (HMPV) is a result of its highly efficient transmission “trinity”: respiratory droplets, direct physical touch, and contaminated environmental surfaces. Because the hmpv virus targets the mucosal surfaces of the eyes, nose, and mouth, it exploits the common ways humans interact in social and clinical settings. Understanding the mechanics of how human metapneumovirus hmpv moves from one host to another is the first step in interrupting the chain of infection, particularly during the high-risk late winter and spring seasons.

The Droplet Pathway: Airborne Proximity

The most common way to contract a metapneumovirus infection is through the inhalation of large respiratory droplets. When an infected individual coughs, sneezes, or even speaks loudly, they expel microscopic “pockets” of fluid containing the hmpv virus. These droplets are relatively heavy and generally travel between three and six feet before gravity pulls them onto nearby surfaces or directly into the respiratory tract of a bystander.

In high-density environments like daycare centers, public transportation, or office spaces, this mode of spread is extremely effective. Because human mpv can be shed in high volumes during the peak of the illness, a single unprotected cough can saturate the immediate air with infectious particles. This is why “respiratory etiquette”—covering the mouth with an elbow or tissue—is the primary defense against droplet-based human metapneumovirus symptoms spreading through a community.

Touch and Fomites: The Indirect Threat

While droplets are a major driver, human metapneumovirus contagious properties are equally potent through direct and indirect contact.

Direct Personal Contact

Direct contact involves the physical transfer of the virus from one person’s skin to another’s. For example, if an infected person rubs their nose and then shakes hands with a colleague, they transfer the hmpv virus to that colleague. The infection is completed through “self-inoculation,” where the healthy person touches their own eyes or mouth, introducing the virus into their system. This is a significant concern in household settings where caregivers are in constant physical contact with symptomatic children.

Surface Survival (Fomites)

The h metapneumovirus can also survive on inanimate objects, known as fomites, for several hours. As an enveloped virus, it is somewhat fragile, but it persists long enough on non-porous surfaces like plastic toys, doorknobs, and countertops to pose a risk. If a child with an hmpv infection plays with a toy and another child touches that toy an hour later, the second child can pick up the virus. Regular disinfection of high-touch surfaces is vital to breaking this cycle of human mpv transmission.

Timing the Spread: Incubation and Shedding

Understanding how is hmpv contagious requires looking at the clock. The virus operates on a specific timeline that allows it to spread even before a person feels unwell.

Incubation Period (3–6 Days): This is the window between the moment the hmpv virus enters your body and the onset of the first human metapneumovirus symptoms. During this time, the virus is busy replicating within the respiratory epithelium.

The Contagious Window: A person is typically most contagious when they are actively symptomatic—coughing and sneezing—as this physically expels the most virus. However, shedding of the metapneumovirus rna can begin 24 to 48 hours before symptoms appear.

Extended Shedding: While most healthy adults stop being contagious after about a week, certain groups remain a transmission risk for much longer. Infants and immunocompromised individuals can shed the virus for several weeks, meaning they can continue to spread the hmpv infection long after they appear to have recovered.

Breaking the Chain of Infection

Because there is currently no specific vaccine for human metapneumovirus hmpv, prevention relies entirely on behavioral “roadblocks” that stop these transmission modes.

• Hand Hygiene: Frequent washing with soap and water or using alcohol-based sanitizers kills the virus on the skin, preventing direct and indirect contact spread.
• Environmental Cleaning: Using EPA-approved disinfectants on common surfaces like light switches and keyboards neutralizes the hmpv virus before it can find a new host.
• Physical Barriers: Wearing masks in crowded areas during the peak season can block the inhalation of large droplets, significantly reducing the risk of a lower respiratory hmpv infection or human metapneumovirus pneumonia.

The Prevention Methods for Human Metapneumovirus

Because there is currently no vaccine to prevent human metapneumovirus (HMPV), the strategy for protection shifts entirely to non-pharmaceutical interventions. These methods are designed to build a “layered defense” that disrupts the virus’s ability to survive in the environment and enter the human body. By targeting the hmpv virus at its points of transmission—droplets, direct touch, and surface contamination—individuals can significantly lower the risk of developing hmpv symptoms or more severe complications like hmpv pneumonia.

The Chemistry of Defense: Why Handwashing Works

The most powerful weapon against human metapneumovirus hmpv is a simple bar of soap. Biologically, HMPV is an enveloped virus, meaning its genetic material is protected by a fragile lipid (fatty) membrane. This structure is its “Achilles’ heel.” The molecules in soap are dual-natured; one end is attracted to water, while the other is attracted to fats. When you wash your hands, the soap molecules wedge themselves into the virus’s lipid envelope and tear it apart, effectively “popping” the virus like a balloon.

To ensure the hmpv virus is fully inactivated and physically removed, the process must be thorough. Mechanical friction for at least 20 seconds is required to reach the crevices of the skin, the backs of the hands, and under the fingernails. While alcohol-based hand sanitizers (at least 60% alcohol) are an excellent secondary option that denatures viral proteins, they cannot “wash away” the neutralized particles or organic material. Therefore, soap and water remain the gold standard for preventing human mpv self-inoculation—the process where you inadvertently move the virus from a contaminated surface to your own eyes, nose, or mouth.

Respiratory Etiquette: Containing the Source

Since metapneumovirus contagious droplets can travel up to six feet, “source control” is a vital hygiene practice. This involves trapping respiratory secretions before they ever enter the shared air space.

The Tissue Method: The most effective way to block the hmpv virus is to use a tissue for every cough or sneeze, followed immediately by disposal and hand hygiene.

The “Vampire” Sneeze: If a tissue isn’t available, coughing into the crook of your elbow (the “vampire” pose) is the next best step. This keeps the droplets off your palms, preventing you from turning your hands into a vehicle for human metapneumovirus hmpv transmission when you touch doorknobs or shake hands.

By practicing strict respiratory etiquette, you protect those around you from inhaling infectious particles that could lead to a lower respiratory hmpv infection. This is especially critical in households with infants or elderly adults, where the risk of human metapneumovirus pneumonia is substantially higher.

Environmental Hygiene: Neutralizing Fomites

The h metapneumovirus can linger on non-porous surfaces like plastic and stainless steel for several hours, making your home or office a potential minefield of “fomites.” To combat this, a regular disinfection routine is necessary, focusing on “high-touch” areas. Effective metapneumovirus treatment for the environment involves using EPA-registered disinfectants. These chemicals are specifically formulated to dissolve the viral envelope on contact.

• Electronic Care: Phones and keyboards are often the most contaminated items. Using alcohol-based wipes can neutralize the hmpv virus without damaging the hardware.
• Contact Time: A common mistake is wiping the surface dry immediately. To kill the hmpv virus, the disinfectant often needs to remain wet on the surface for several minutes (the “dwell time”) as specified on the product label.
• Frequency: During the peak spring season, daily disinfection of shared items like remote controls and faucet handles can break the chain of indirect hmpv infection in a household.

Behavior Modification: Stopping Self-Inoculation

Perhaps the most difficult yet effective prevention method is the conscious avoidance of touching your face. The mucosal membranes of the eyes, nose, and mouth are the only “gateways” the hmpv virus can use to enter your respiratory system. Even if your hands have picked up the metapneumovirus rna from a contaminated surface, the virus cannot infect you through the skin of your palms. It is only when you rub your eyes or touch your nose that the hmpv infection begins. By training yourself to keep your hands away from your face, you provide a final, impenetrable barrier against the virus.

The At-risk Groups For Devere Human Metapneumovirus Infection

While human metapneumovirus (HMPV) typically manifests as a manageable “nuisance” cold for the general population, the hmpv virus is a major opportunistic threat to specific vulnerable demographics. For these at-risk groups, the metapneumovirus infection is not merely a series of sniffles but a high-stakes challenge to their respiratory and immune systems. The transition from a mild hmpv infection to life-threatening hmpv pneumonia is often a direct reflection of the host’s inability to keep viral replication in check due to age, anatomy, or underlying medical frailty.

The Pediatric Burden: Why Infants Face the Greatest Risk

In the world of pediatric medicine, human metapneumovirus hmpv is recognized as the second leading cause of hospitalization for lower respiratory infections, trailing only behind RSV. The vulnerability of infants and children under five is driven by a “perfect storm” of biological factors. Most importantly, their immune systems are still in the “learning phase.” While maternal antibodies provide a temporary shield, this protection fades within months, leaving the infant to face their first metapneumovirus infection with no immunological memory.

Anatomical differences also play a critical role in the severity of human mpv in children. Because an infant’s airways (bronchioles) are remarkably small and narrow, even a minor amount of inflammation or mucus production can lead to a complete blockage. This results in the classic hmpv symptoms of bronchiolitis: wheezing, rapid breathing, and visible “retractions” where the skin pulls in around the ribs as the child struggles for air. For these tiny patients, the hmpv virus is a structural threat that often necessitates hospitalization for oxygen therapy and hydration.

Immunosenescence and the Elderly: A Silent Threat

For adults over the age of 65, the risk associated with human metapneumovirus in adults is largely driven by a process called immunosenescence. As we age, the immune system’s ability to mount a rapid and coordinated defense naturally declines. This means that a metapneumovirus infection that a 30-year-old would clear in three days might persist in an older adult for weeks, allowing the virus to travel deep into the lungs and cause human metapneumovirus pneumonia.

The risk is compounded by the high prevalence of chronic conditions in older populations. Human mpv is a notorious “exacerbator” of pre-existing health problems. In an older adult with Chronic Obstructive Pulmonary Disease (COPD) or congestive heart failure, the added stress of an hmpv infection can trigger a systemic crisis. The inflammation from the virus doesn’t just damage lung tissue; it strains the heart and reduces overall oxygen saturation, making hmpv symptoms adults experience in this age group a leading cause of emergency room visits during the spring months.

The Immunocompromised: HMPV as an Opportunistic Killer

Perhaps the most precarious at-risk group includes individuals whose immune systems have been suppressed by disease or medical treatment. This group includes cancer patients undergoing chemotherapy, organ transplant recipients, and those living with advanced HIV. For these individuals, the hmpv virus is not a seasonal annoyance but a potentially fatal opportunistic pathogen.

In a healthy person, T-cells and antibodies quickly neutralize the metapneumovirus rna. However, in a transplant patient on immunosuppressants, the virus can replicate unchecked. This often leads to a “high-load” hmpv infection characterized by extensive and irreversible lung damage. For these patients, treatment for hmpv is often difficult because the body lacks the internal machinery to fight back, turning a common respiratory virus into a primary cause of mortality.

How is Human Metapneumovirus Diagnosed and Treated?

The diagnosis and management of human metapneumovirus (HMPV) represent a unique challenge in clinical medicine because the virus lacks a “distinctive” physical signature. Because hmpv symptoms—such as a rasping cough, congestion, and fever—are virtually identical to those of the flu or RSV, physicians cannot rely on a physical exam alone. Instead, the process must move from identifying the symptoms of hmpv to utilizing high-precision molecular tools to identify the metapneumovirus rna directly.

The Gold Standard: Human Metapneumovirus PCR

The only way to definitively identify an hmpv infection is through laboratory testing. In modern clinical settings, the human metapneumovirus pcr (RT-PCR) is the preferred diagnostic method. This test works by taking a respiratory specimen—usually via a nasal or throat swab—and amplifying the viral genetic material until it is detectable.

The hmpv pcr is remarkably sensitive and can identify the virus even when the viral load is relatively low. This is particularly important for human metapneumovirus in adults, who may shed less virus than infants but still suffer from severe hmpv pneumonia. In many hospitals, this test is part of a “respiratory panel” that simultaneously screens for a dozen different viruses. While older methods like viral cultures exist, they are often too slow to be clinically useful, as the hmpv virus can take weeks to grow in a lab, whereas a PCR can provide results in just a few hours.

The Typical Season for HMPV Outbreaks

The typical season for HMPV outbreaks is one of the most distinctive features of the virus, often acting as the “final wave” of the annual respiratory cycle. While many people associate viral infections strictly with the dark, cold days of mid-winter, human metapneumovirus hmpv is notorious for its late arrival. Understanding this timing is essential for both public health officials and families, as it explains why a severe respiratory illness can sweep through a community just as the weather begins to improve.

The Late Winter and Spring Peak

In temperate climates, such as the Northern Hemisphere, human metapneumovirus hmpv exhibits a remarkably consistent schedule. While influenza and RSV activity typically peak in December and January, the hmpv virus usually begins its upward climb in February, reaching its maximum intensity in March and April. In some years, the season can linger as late as May or June.

This specific window is often referred to as a “staggered” seasonality. For healthcare providers, this means that when a patient presents with hmpv symptoms in April—long after the flu has faded—the hmpv virus is the primary suspect. Because the virus thrives in the transitional weather of early spring, it effectively extends the duration of the “sick season” by several months, catching many people off guard who have already lowered their defenses.

The Implications of Seasonal Overlap

The fact that the hmpv infection season overlaps with the tail end of the RSV and flu seasons creates a complex diagnostic environment. This “co-circulation” means that a person can actually be infected with two viruses at once—for example, the flu and HMPV—which can significantly increase the severity of human metapneumovirus symptoms.

For hospitals and pediatric clinics, the late-spring surge of metapneumovirus infection requires sustained staffing and resources. Pediatric wards often see a second spike in admissions for bronchiolitis and hmpv pneumonia just as they are beginning to recover from the mid-winter RSV peak. This is why the use of a human metapneumovirus pcr is so vital during this time; it allows doctors to quickly identify which virus is driving the current wave of hospitalizations and manage the patient load accordingly.

Why Seasonality Matters for Prevention

Because the h metapneumovirus remains active well into the spring, it is a common mistake for individuals to stop practicing rigorous hygiene too early. The predictable nature of the hmpv virus outbreaks serves as a reminder that respiratory viruses are not strictly “winter” problems.

Sustained Vigilance: Preventative measures like frequent handwashing and disinfecting high-touch surfaces must be maintained through April and May to avoid hmpv symptoms adults and children face during the spring peak.

Targeted Protection: Families with high-risk individuals—such as infants or those with human metapneumovirus in adults risk factors like COPD—should remain cautious of large gatherings and public spaces until the local HMPV activity officially declines.

Are There Long-term Complications Associated With a Severe HMPV Infection?

While most cases of human metapneumovirus hmpv resolve within two weeks, a severe hmpv infection—particularly one that occurs during the critical window of lung development in infancy—can leave a lasting “imprint” on a person’s respiratory health. The transition from an acute metapneumovirus infection to chronic complications is not merely a matter of a lingering cough; it involves fundamental changes to the structure and sensitivity of the airways.

The Link to Pediatric Asthma and Wheezing

The most significant long-term complication of severe human metapneumovirus symptoms in early childhood is the increased risk of developing asthma. Clinical studies have shown that infants hospitalized with hmpv virus-induced bronchiolitis are significantly more likely to experience recurrent wheezing episodes throughout their childhood.

This occurs because the intense inflammation during a severe hmpv infection can lead to “airway remodeling.” During this process, the delicate tissues of the small airways may heal with structural changes that make them permanently narrower or more prone to swelling. This results in airway hyperreactivity, where the lungs become oversensitive to future triggers like pollen, cold air, or even other common colds, essentially setting the stage for a lifelong asthma diagnosis.

Impact on Lung Function and Capacity

In vulnerable populations, such as those who developed human metapneumovirus pneumonia, there is a risk of long-term reductions in lung function. While the body is excellent at healing, severe viral damage to the alveoli (the air sacs where oxygen exchange happens) can sometimes lead to minor scarring. For older adults or those with pre-existing human metapneumovirus in adults risk factors, a severe bout of hmpv pneumonia can lead to:

Decreased Exercise Tolerance: A permanent, though often slight, reduction in the ability of the lungs to oxygenate the blood during physical exertion.

COPD Exacerbation Cycles: For those who already have Chronic Obstructive Pulmonary Disease, an hmpv infection can accelerate the progression of the disease, leading to a “new normal” of lower lung capacity after the virus has cleared.

The “Second Hit” Phenomenon

In the immunocompromised or those with severe initial cases, human metapneumovirus hmpv can occasionally predispose the lungs to secondary bacterial infections. If the viral infection causes significant damage to the “cilia” (the tiny hairs that sweep mucus out of the lungs), the respiratory tract loses its primary defense mechanism. This can lead to a cycle of recurrent bacterial pneumonia or chronic bronchitis, as the lungs struggle to clear debris effectively long after the metapneumovirus rna is no longer detectable.

Conclusion

While human metapneumovirus is often mild and self-limiting in healthy individuals, it can lead to severe respiratory illness in vulnerable populations such as young children, the elderly, and those with compromised immune systems. Early identification and proper management can help prevent complications and reduce the spread of this contagious virus.

By being informed about HMPV, its symptoms, and how it spreads, you can take the necessary precautions to protect yourself and others. Preventative measures such as good hygiene practices, covering coughs and sneezes, and staying home when ill can help reduce transmission. If you suspect you or someone you know may have contracted human metapneumovirus, it’s important to seek medical attention, especially if symptoms worsen or persist.

Read more: 7 Symptoms of Hyperparathyroid Disease You Should Never Ignore

Frequently Asked Questions (FAQ) About Human Metapneumovirus

What is human metapneumovirus (HMPV)?

Human metapneumovirus (HMPV) is a respiratory virus that primarily affects the respiratory system, causing symptoms similar to the common cold, flu, or even pneumonia. It was first identified in 2001 and is part of the paramyxovirus family, which also includes viruses like respiratory syncytial virus (RSV). The virus can affect individuals of all ages but is particularly concerning for young children, the elderly, and those with weakened immune systems.

How does human metapneumovirus spread?

Human metapneumovirus spreads through respiratory droplets when an infected person coughs, sneezes, or talks. It can also be transmitted by touching surfaces contaminated with the virus and then touching the face, particularly the eyes, nose, or mouth. The virus is highly contagious, and outbreaks tend to occur in colder months when people are more likely to congregate in closed spaces. Proper hygiene, such as frequent handwashing and covering coughs and sneezes, can help reduce the spread of HMPV.

What are the symptoms of human metapneumovirus?

The symptoms of human metapneumovirus resemble those of other respiratory illnesses like the flu or the common cold. Common symptoms include a runny or stuffy nose, cough, sore throat, fever, and fatigue. In more severe cases, individuals, especially young children and the elderly, may experience wheezing, shortness of breath, and chest pain. While many people recover without requiring medical intervention, some individuals, particularly those with preexisting conditions, may develop more severe respiratory issues.

Is there a treatment for human metapneumovirus?

There is no specific antiviral treatment for human metapneumovirus. Management typically focuses on relieving symptoms. Over-the-counter medications such as pain relievers and fever reducers can help alleviate discomfort. For more severe cases, particularly those involving difficulty breathing or pneumonia, medical intervention may be required. This may include supplemental oxygen or hospitalization, especially for vulnerable populations. Rest, hydration, and proper nutrition also play important roles in recovery.

Can human metapneumovirus be prevented?

Prevention of human metapneumovirus mainly involves practicing good hygiene. Regular handwashing with soap and water, avoiding close contact with infected individuals, and covering coughs and sneezes can help reduce the spread of the virus. Additionally, cleaning and disinfecting commonly touched surfaces, especially during flu season or when outbreaks occur, can prevent the virus from spreading. Since there is no vaccine for HMPV, these preventative measures are crucial in controlling transmission.

Who is most at risk for severe illness from human metapneumovirus?

While human metapneumovirus can affect anyone, individuals at higher risk for severe illness include young children, the elderly, and people with weakened immune systems, such as those with cancer, HIV, or chronic respiratory diseases. People with preexisting conditions like asthma, chronic obstructive pulmonary disease (COPD), or heart disease may also be more susceptible to complications from the virus. It’s important for these groups to seek medical attention if they experience worsening symptoms.

Sources

• Centers for Disease Control and Prevention (CDC) – Human Metapneumovirus
• American Lung Association – Human Metapneumovirus
• National Institutes of Health (NIH) – Human Metapneumovirus Overview
• WebMD – Human Metapneumovirus: Symptoms, Causes, and Treatment
• Johns Hopkins Medicine – Human Metapneumovirus Infection